Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Current Assets (2019 - 2025)

Historic Current Assets for IDEAYA Biosciences (IDYA) over the last 7 years, with Q4 2025 value amounting to $666.7 million.

  • IDEAYA Biosciences' Current Assets fell 333.27% to $666.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $666.7 million, marking a year-over-year decrease of 333.27%. This contributed to the annual value of $666.7 million for FY2025, which is 333.27% down from last year.
  • According to the latest figures from Q4 2025, IDEAYA Biosciences' Current Assets is $666.7 million, which was down 333.27% from $802.7 million recorded in Q3 2025.
  • In the past 5 years, IDEAYA Biosciences' Current Assets registered a high of $932.2 million during Q3 2024, and its lowest value of $251.0 million during Q4 2021.
  • Over the past 5 years, IDEAYA Biosciences' median Current Assets value was $492.0 million (recorded in 2023), while the average stood at $508.4 million.
  • Its Current Assets has fluctuated over the past 5 years, first skyrocketed by 24444.92% in 2021, then plummeted by 1690.98% in 2022.
  • Over the past 5 years, IDEAYA Biosciences' Current Assets (Quarter) stood at $251.0 million in 2021, then surged by 47.59% to $370.5 million in 2022, then soared by 43.78% to $532.6 million in 2023, then rose by 29.49% to $689.7 million in 2024, then dropped by 3.33% to $666.7 million in 2025.
  • Its Current Assets stands at $666.7 million for Q4 2025, versus $802.7 million for Q3 2025 and $685.6 million for Q2 2025.